Advocacy intelligence hub — real-time data for patient organizations
Ray Therapeutics, Inc. — PHASE1
Ray Therapeutics, Inc.
Erasme University Hospital — NA
Kiora Pharmaceuticals, Inc. — PHASE1, PHASE2
Center for Eye Research Australia
4D Molecular Therapeutics — PHASE1
NightstaRx Ltd, a Biogen Company — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Miguel C Seabra, MD PhD
Imperial College London
Andrew R Webster, MD
UCL Institute of Ophthalmology and Moorfields Eye Hospital
Susan M Downes, MD
Oxford University Hospitals NHS Trust
Tanya Tolmachova, PhD
Imperial College London
Andrew J Lotery, MD
University of Southampton and Southampton University Hospitals Trust
Jessica IW Morgan, PhD
University of Pennsylvania